Hunan Fangsheng Pharmaceutical Co., Ltd. (SHA:603998)
China · Delayed Price · Currency is CNY 10.98
+0.16 (1.48%)
Apr 29, 2026, 3:00 PM CST
SHA:603998 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,791 | 1,746 | 1,710 | 1,569 | 1,751 | 1,535 |
Other Revenue | - | - | 67.69 | 59.09 | 41.27 | 32.12 |
| 1,791 | 1,746 | 1,777 | 1,629 | 1,792 | 1,567 | |
Revenue Growth (YoY) | 1.93% | -1.75% | 9.15% | -9.12% | 14.36% | 22.54% |
Cost of Revenue | 480.39 | 489.54 | 517.01 | 522.25 | 589.28 | 566.27 |
Gross Profit | 1,311 | 1,257 | 1,260 | 1,106 | 1,203 | 1,001 |
Selling, General & Admin | 784.23 | 756.88 | 846.57 | 804.8 | 940.45 | 798.94 |
Research & Development | 158.77 | 154.47 | 139.21 | 107.93 | 70.4 | 51.4 |
Other Operating Expenses | 21.76 | 19.85 | 23.3 | 29.27 | 28.55 | 24.33 |
Operating Expenses | 964.76 | 931.2 | 1,013 | 942.99 | 1,049 | 877.34 |
Operating Income | 345.99 | 325.7 | 247.14 | 163.31 | 153.98 | 123.37 |
Interest Expense | - | - | -21.79 | -20.81 | -22.95 | -18.39 |
Interest & Investment Income | 2.1 | 1.69 | 48.22 | 10.64 | 171 | 1.77 |
Currency Exchange Gain (Loss) | - | - | - | - | 0.16 | -0.57 |
Other Non Operating Income (Expenses) | -17.32 | -15.77 | -1.25 | -2.22 | -15.14 | -2.46 |
EBT Excluding Unusual Items | 330.77 | 311.62 | 272.32 | 150.92 | 287.05 | 103.72 |
Impairment of Goodwill | - | - | -5.38 | - | - | - |
Gain (Loss) on Sale of Investments | 0.81 | - | -0.82 | -5.46 | -0.06 | -21.17 |
Gain (Loss) on Sale of Assets | 36.12 | 51.39 | 0.7 | 11.38 | -1.03 | -0.94 |
Asset Writedown | -9.99 | -9.77 | - | - | - | - |
Other Unusual Items | - | - | 19.17 | 46.5 | 40.63 | 9.18 |
Pretax Income | 357.71 | 353.24 | 285.99 | 203.34 | 326.57 | 90.79 |
Income Tax Expense | 55.94 | 50.61 | 36.14 | 23.71 | 49.87 | 20.87 |
Earnings From Continuing Operations | 301.77 | 302.64 | 249.85 | 179.62 | 276.71 | 69.92 |
Minority Interest in Earnings | 4.75 | 3.75 | 5.37 | 7.2 | 9.15 | 0.12 |
Net Income | 306.52 | 306.39 | 255.22 | 186.82 | 285.85 | 70.04 |
Net Income to Common | 306.52 | 306.39 | 255.22 | 186.82 | 285.85 | 70.04 |
Net Income Growth | 12.16% | 20.05% | 36.61% | -34.64% | 308.13% | 9.79% |
Shares Outstanding (Basic) | 438 | 438 | 433 | 434 | 433 | 438 |
Shares Outstanding (Diluted) | 438 | 438 | 440 | 445 | 433 | 438 |
Shares Change (YoY) | -0.64% | -0.53% | -1.08% | 2.70% | -1.06% | 2.93% |
EPS (Basic) | 0.70 | 0.70 | 0.59 | 0.43 | 0.66 | 0.16 |
EPS (Diluted) | 0.70 | 0.70 | 0.58 | 0.42 | 0.66 | 0.16 |
EPS Growth | 12.88% | 20.69% | 38.09% | -36.36% | 312.50% | 6.67% |
Free Cash Flow | 335.74 | 282.12 | 100.16 | -131.24 | 130.38 | 0.92 |
Free Cash Flow Per Share | 0.77 | 0.65 | 0.23 | -0.29 | 0.30 | 0.00 |
Dividend Per Share | - | - | 0.250 | 0.290 | 0.350 | 0.150 |
Dividend Growth | - | - | -13.79% | -17.14% | 133.33% | 25.00% |
Gross Margin | 73.18% | 71.97% | 70.91% | 67.93% | 67.12% | 63.86% |
Operating Margin | 19.32% | 18.65% | 13.90% | 10.03% | 8.59% | 7.87% |
Profit Margin | 17.11% | 17.54% | 14.36% | 11.47% | 15.95% | 4.47% |
Free Cash Flow Margin | 18.74% | 16.15% | 5.63% | -8.06% | 7.28% | 0.06% |
EBITDA | 423.51 | 402.34 | 320.22 | 235.04 | 223.65 | 190.74 |
EBITDA Margin | 23.64% | 23.04% | 18.02% | 14.43% | 12.48% | 12.17% |
D&A For EBITDA | 77.52 | 76.64 | 73.08 | 71.73 | 69.67 | 67.38 |
EBIT | 345.99 | 325.7 | 247.14 | 163.31 | 153.98 | 123.37 |
EBIT Margin | 19.32% | 18.65% | 13.90% | 10.03% | 8.59% | 7.87% |
Effective Tax Rate | 15.64% | 14.33% | 12.64% | 11.66% | 15.27% | 22.99% |
Revenue as Reported | - | - | 1,777 | 1,629 | 1,792 | 1,567 |
Advertising Expenses | - | - | 145.33 | 77.28 | 34.32 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.